Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
|Articles|May 2, 2016
- Pharmaceutical Technology-05-02-2016
- Volume 40
- Issue 5
Ultracentrifuge Allows for Multi-Wavelength Analysis
The Optima AUC from Beckman Coulter Life Sciences is an ultracentrifuge that determines molecular weight, size shape, and polydispersity.
The Optima AUC from Beckman Coulter Life Sciences is an ultracentrifuge that determines molecular weight, size shape, and polydispersity. The Optima AUC has a 38.1-cm (15-inch diagonal) touch-screen with the ability to export data locally or remotely. The optics are contained outside the rotor chamber, reducing the impact of the g-force on the optics. The Optima AUC also allows molecules to float free and unbound so that researchers are able to characterize them in their native state. The ultracentrifuge can perform multi-wavelength analysis and allows for the development of new detection systems.
Articles in this issue
over 10 years ago
Forced Degradation Studies for Biopharmaceuticalsover 10 years ago
Choosing Containment Strategies For Highly Potent APIsover 10 years ago
Visions for the Future of Biopharma Manufacturingover 10 years ago
Outsourcing of Biomanufacturing in 2016over 10 years ago
Pharmaceutical Quality: Where Do We Need to Go from Here?over 10 years ago
Reporting Quality Metrics to FDAover 10 years ago
Significant Revisions and Updates to the European Pharmacopoeiaover 10 years ago
The Value of Saving LivesRelated to this article
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
The new initiative aims to apply traceable AI and science to expand care worldwide by translating discovery into tools that accelerate drug development.
Sanjay Konagurthu, PhD, senior director, Science and Innovation at Thermo Fisher Scientific, provides an update on the progress of AI and machine learning used in drug delivery.
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5